#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

On Tues­day I had a chance to sit down with 4 top R&D chiefs of some of the biggest or­ga­ni­za­tions in the in­dus­try. There’s no ques­tion that the pan­dem­ic has been re­shap­ing R&D, and I want­ed to talk about the in­ter­nal and ex­ter­nal forces they’re ex­pe­ri­enc­ing that are con­tin­u­ing to re­make our ideas about re­search and de­vel­op­ment. — John Car­roll

John Car­roll:

Okay, every­body. This is John Car­roll. I’m back. I’m the ed­i­tor of End­points News back with you with our lat­est pan­el dis­cus­sion re­lat­ed to R&D. I’ve got a great pan­el here to­day, and I re­al­ly put a lot of thought in­to who I want­ed to have on this pan­el, and I think in a lot of dif­fer­ent re­spects it’s just gold all the way through.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN